1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a: results of a preliminary study

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  1998-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.64.2.204PMID 9489531PMCID PMC2169932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy.

  1996cited by this paper
• Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

  1995cited by this paper
• Does interferon beta cause initial exacerbation of multiple sclerosis?

  1995cited by this paper
• Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes

  1995cited by this paper
• Interferon-β downregulates interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells

  1995cited by this paper
• Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients.

  1995cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Magnetic resonance imaging and spectroscopy in multiple sclerosis.

  1995cited by this paper
• Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

  1995cited by this paper
• Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells.

  1995cited by this paper
• Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes.

  1995cited by this paper
• Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein

  1995cited by this paper
• High Resolution Proton NMR Spectroscopy of Multiple Sclerosis Lesions

  1995cited by this paper
• Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions.

  1994cited by this paper
• RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis

  1994cited by this paper
• Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging

  1994cited by this paper
• Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis

  1994cited by this paper
• Interferon β decreases T cell activation and interferon γ production in multiple sclerosis

  1993cited by this paper
• Inositol trisphosphate and calcium signalling

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• The proton NMR spectrum in acute EAE: The significance of the change in the Cho:Cr ratio

  1993cited by this paper
• Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types

  1993cited by this paper
• A multiparametric data analysis showing the potential of localized proton MR spectroscopy of the brain in the metabolic characterization of neurological diseases.

  1993cited by this paper
• Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques

  1992cited by this paper
• Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo

  1992cited by this paper
• Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis

  1991cited by this paper
• Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis

  1991cited by this paper
• Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis

  1991cited by this paper
• Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease

  1990cited by this paper
• Interfer beta augments supperssor cell function in multiple sclerosis

  1990cited by this paper
• In vivo proton spectroscopy in presence of eddy currents

  1990cited by this paper
• The role of NMR imaging in the assessment of multiple sclerosis.

  1988cited by this paper
• Spatially localized 1H NMR spectra of metabolites in the human brain.

  1988cited by this paper
• Inositol trisphosphate and calcium signaling.

  1988cited by this paper
• The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study.

  1987cited by this paper
• Biochemistry and the Central Nervous System (5th Ed.)

  1986cited by this paper
• N‐Acetyl‐Aspartyl‐Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC Method

  1984cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Cerebrovascular Disease

  1967cited by this paper
• Studies on the distribution of N-acetyl-L-aspartic acid in brain.

  1957cited by this paper
• Spatially localized 1 H NMR spectra of metabolites in the human brain ( N-acetylaspartate / lactate / surface coils / neurochemistry )

  year unknowncited by this paper

• Exploring neuroinflammation: A key driver in neuropathic pain disorders.

  2024cites this paper
• Peripheral inflammation is associated with alterations in brain biochemistry and mood: evidence from in vivo proton magnetic resonance spectroscopy study

  2023cites this paper
• Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy

  2022cites this paper
• Creatine and multiple sclerosis

  2020cites this paper
• Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

  2019cites this paper
• Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives

  2018cites this paper
• The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials

  2017cites this paper
• Spectroscopie cérébrale par résonance magnétique : techniques et principales applications cliniques

  2014cites this paper
• Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course

  2013cites this paper
• Magnetic resonance monitoring of lesion evolution in multiple sclerosis

  2013cites this paper
• , damage and predictors of clinical course Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue

  2013cites this paper
• 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders.

  2013cites this paper
• Investigation of brain tissue water NMR response by optimised quantitative single-voxel proton magnetic resonance spectroscopy

  2013influential citation
• MR Spectroscopy in Multiple Sclerosis - A New Piece of the Puzzle or Just a New Puzzle

  2012cites this paper
• MRI measures of neuroprotection and repair in multiple sclerosis.

  2011cites this paper
• Use of Imaging in Multiple Sclerosis

  2010cites this paper
• MRI IN MULTIPLE SCLEROSIS

  2010cites this paper
• Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics

  2010cites this paper
• Brain Magnetic Resonance Spectroscopy

  2009cites this paper
• Proton magnetic resonance spectroscopy in multiple sclerosis.

  2009cites this paper
• MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study

  2009cites this paper
• Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.

  2009cites this paper
• The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

  2008cites this paper
• THE ROLE OF ADVANCED MAGNETIC RESONANCE IMAGING

  2008cites this paper
• (1)H MR spectroscopy of inflammation, infection and ischemia of the brain.

  2008cites this paper
• The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.

  2008cites this paper
• Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.

  2008cites this paper
• Inflammatory Disorders of the Nervous System. Pathogenesis, Immunology, and Clinical Management, 1st ed., Alireza Minagar, J. Steven Alexander (Eds.). Humana Press (2005), 362pp., US$155, ISBN: 1588294242

  2007cites this paper
• MEASURING AND ASSESSING NEURODEGENERATION AND NEUROPROTECTION: THE ROLE OF MRI *

  2007cites this paper
• Neurodegeneration and -protection in autoimmune CNS inflammation.

  2007cites this paper
• Interferon Beta-1b May Reverse Axonal Dysfunction in Multiple Sclerosis

  2007cites this paper
• Quantitative diffusion weighted imaging measures in patients with multiple sclerosis

  2007cites this paper
• Guidelines for using proton MR spectroscopy in multicenter clinical MS studies

  2007cites this paper
• Design for the Next Trials of Neurodegeneration

  2007cites this paper
• Multiple Sclerosis and Demyelinating Diseases

  2007influential citation
• Review article Neurodegeneration and -protection in autoimmune CNS inflammation

  2007cites this paper
• Proton MR Spectroscopy

  2007cites this paper
• Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis

  2006cites this paper
• EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

  2006cites this paper
• Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions.

  2006cites this paper
• EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

  2006cites this paper
• Clinical trials in multiple sclerosis: methodological issues

  2005cites this paper
• Magnetic Resonance Spectroscopy in the Monitoring of Multiple Sclerosis

  2005cites this paper
• Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging

  2005cites this paper
• Multiple Sclerosis: Other MR Techniques

  2005cites this paper
• Assessing Treatment Effects on Axonal Loss - Evidence from MRI Monitored Clinical Trials

  2005cites this paper
• Neuroprotective Effects of Interferon-β in Multiple Sclerosis

  2005cites this paper
• Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis.

  2005cites this paper
• Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis

  2005cites this paper
• Magnetic Resonance Imaging Monitoring of Multiple Sclerosis Lesion Evolution

  2005cites this paper
• 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review.

  2005cites this paper
• Imaging of multiple sclerosis: Role in neurotherapeutics

  2005cites this paper
• Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis.

  2005cites this paper
• 7 Neuroprotective Effects of Interferon-β in Multiple Sclerosis

  2005cites this paper
• Quantitative 1H‐MRS of healthy human cortex, hippocampus, and thalamus: Metabolite concentrations, quantification precision, and reproducibility

  2004cites this paper
• Assessing treatment effects on axonal loss—evidence from MRI monitored clinical trials

  2004influential citation
• Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy

  2004cites this paper
• The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials

  2004cites this paper
• Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

  2003influential citation
• Antiretroviral Treatment Alters Relationship between Mcp-1 and Neurometabolites in HIV Patients

  2003cites this paper
• [Hydrogen spectroscopy in neurology].

  2003cites this paper
• In vivo Magnetic Resonance Spectroscopy • • In neurosciences

  2003cites this paper
• The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis.

  2003cites this paper
• [Diagnostic and prognostic potential of MRI in multiple sclerosis].

  2003cites this paper
• Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-β therapy on absolute metabolite concentrations

  2002cites this paper
• Magnetic Resonance Imaging of Multiple Sclerosis

  2002cites this paper
• Clinical trials and clinical practice in multiple sclerosis: Conventional and emerging magnetic resonance imaging technologies

  2002cites this paper
• Clinical Magnetic Resonance Spectroscopy

  2001cites this paper
• Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.

  2001cites this paper
• EXPRESSION OF TNF-α mRNA BY PERIPHERAL BLOOD MONONUCLEAR CELLS OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH IFN-β 1A

  2001cites this paper
• Correlations between Magnetic Resonance Spectroscopy and Other Magnetic Resonance Parameters in Multiple Sclerosis

  2001cites this paper
• Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis.

  2001cites this paper
• Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b

  2001cites this paper
• Interferon β1a Therapy Changes Lipoprotein Metabolism in Patients with Multiple Sclerosis

  2000cites this paper
• Brain Magnetic Resonance Spectroscopy

  2000cites this paper
• Kernspintomografie bei Multipler Sklerose

  2000cites this paper
• Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis.

  2000cites this paper
• Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study.

  2000influential citation
• [Nuclear magnetic resonance tomography in multiple sclerosis].

  2000cites this paper
• [Magnetic resonance spectroscopy in multiple sclerosis].

  2000cites this paper
• The role of magnetic resonance in the assessment of multiple sclerosis.

  2000cites this paper
• Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis.

  1999cites this paper
• Digitized image analysis reveals diffuse abnormalities in normal-appearing white matter during acute experimental autoimmune encephalomyelitis.

  1998cites this paper
• Digitized image analysis reveals diffuse abnormalities in normal‐appearing white matter during acute experimental autoimmune encephalomyelitis

  1998cites this paper